Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1993 Apr;69(4):293–297. doi: 10.1136/hrt.69.4.293

Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure.

R J MacFadyen 1, K R Lees 1, J L Reid 1
PMCID: PMC1025039  PMID: 8387806

Abstract

OBJECTIVE--Comparison of the first dose responses to low dose constant rate infusions of diacid angiotensin converting enzyme (ACE) inhibitors. DESIGN--Double blind, randomised, placebo controlled, parallel group prospective study. SETTING--General hospital inpatient admissions for supervised diuretic withdrawal (24-48 hours) and the introduction of ACE inhibitor treatment. PATIENTS--36 unselected elderly (aged 60-87 years) patients with symptomatic but stable chronic cardiac failure (New York Heart Association grades II-IV). ACE inhibitor started under double blind conditions with blood pressure monitoring. INTERVENTION--Patients were randomly allocated to receive intravenous placebo (saline), enalaprilat (1.5 mg over six hours) or perindoprilat (1 mg over six hours) by constant rate intravenous infusion (5 ml/hour). The protocol allowed for discontinuation of infusion if mean arterial blood pressure fell by 30% from the value before treatment. MAIN OUTCOME MEASURES--Blood pressure and heart rate responses, drug concentration, plasma renin, and ACE activities. RESULTS--The three groups had similar age, severity of heart failure, diuretic dose before treatment, plasma renin activity, and serum electrolyte state. All patients remained symptom free throughout the study. Infusions were only ended early with active treatment: 5/12 perindoprilat cases, (mean (SD) dose 0.88 (0.18) mg, and 5/12 enalaprilat cases (mean (SD) dose 1.2 (0.4) mg. Both active treatments lowered mean arterial pressure until discontinuation of infusion. Heart rate was not altered. Two patients (one perindoprilat, one enalaprilat) showed transient and symptom free renal impairment. CONCLUSIONS--Slow intravenous infusion of diacid ACE inhibitors may allow safe initiation of treatment in patients with heart failure and with activated renin angiotensin systems. The similar effects of intravenous perindoprilat and enalaprilat on blood pressure contrast with previously reported differences when perindopril and enalapril were given orally.

Full text

PDF
293

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chiknas S. G. A liquid chromatography-assisted assay for angiotensin-converting enzyme (peptidyl dipeptidase) in serum. Clin Chem. 1979 Jul;25(7):1259–1262. [PubMed] [Google Scholar]
  2. De Marco T., Daly P. A., Liu M., Kayser S., Parmley W. W., Chatterjee K. Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure. J Am Coll Cardiol. 1987 May;9(5):1131–1138. doi: 10.1016/s0735-1097(87)80318-2. [DOI] [PubMed] [Google Scholar]
  3. Derkx F. H., Tan-Tjiong H. L., Man in 't Veld A. J., Schalekamp M. P., Schalekamp M. A. Activation of inactive plasma renin by plasma and tissue kallikreins. Clin Sci (Lond) 1979 Oct;57(4):351–357. doi: 10.1042/cs0570351. [DOI] [PubMed] [Google Scholar]
  4. Dickstein K., Aarsland T., Tjelta K., Cirillo V. J., Gomez H. J. A comparison of hypotensive responses after oral and intravenous administration of enalapril and lisinopril in chronic heart failure. J Cardiovasc Pharmacol. 1987 Jun;9(6):705–710. doi: 10.1097/00005344-198706000-00011. [DOI] [PubMed] [Google Scholar]
  5. Fabris B., Jackson B., Kohzuki M., Perich R., Johnston C. I. Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure. Clin Exp Pharmacol Physiol. 1990 Apr;17(4):309–314. doi: 10.1111/j.1440-1681.1990.tb01326.x. [DOI] [PubMed] [Google Scholar]
  6. Hornung R. S., Hillis W. S. The acute haemodynamic effects of intravenous enalaprilic acid (MK422) in patients with left ventricular dysfunction. Br J Clin Pharmacol. 1987 Jan;23(1):29–33. doi: 10.1111/j.1365-2125.1987.tb03005.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Johnston C. I. Biochemistry and pharmacology of the renin-angiotensin system. Drugs. 1990;39 (Suppl 1):21–31. doi: 10.2165/00003495-199000391-00005. [DOI] [PubMed] [Google Scholar]
  8. Kubo S. H., Cody R. J., Laragh J. H., Prida X. E., Atlas S. A., Yuan Z., Sealey J. E. Immediate converting-enzyme inhibition with intravenous enalapril in chronic congestive heart failure. Am J Cardiol. 1985 Jan 1;55(1):122–126. doi: 10.1016/0002-9149(85)90312-1. [DOI] [PubMed] [Google Scholar]
  9. Lamas G. A., Pfeffer M. A. Left ventricular remodeling after acute myocardial infarction: clinical course and beneficial effects of angiotensin-converting enzyme inhibition. Am Heart J. 1991 Apr;121(4 Pt 1):1194–1202. doi: 10.1016/0002-8703(91)90682-8. [DOI] [PubMed] [Google Scholar]
  10. Linz W., Schölkens B. A., Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A. 1989;11(7):1325–1350. doi: 10.3109/10641968909038172. [DOI] [PubMed] [Google Scholar]
  11. MacFadyen R. J., Lees K. R., Reid J. L. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Br Heart J. 1991 Sep;66(3):206–211. doi: 10.1136/hrt.66.3.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. MacFadyen R. J., Lees K. R., Reid J. L. Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers. Br J Clin Pharmacol. 1992 Aug;34(2):115–121. doi: 10.1111/j.1365-2125.1992.tb04119.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. MacFadyen R. J., Lees K. R., Reid J. L. Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. Br J Clin Pharmacol. 1991 Jan;31(1):1–13. doi: 10.1111/j.1365-2125.1991.tb03851.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nabel E. G., Topol E. J., Galeana A., Ellis S. G., Bates E. R., Werns S. W., Walton J. A., Muller D. W., Schwaiger M., Pitt B. A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction. J Am Coll Cardiol. 1991 Feb;17(2):467–473. doi: 10.1016/s0735-1097(10)80117-2. [DOI] [PubMed] [Google Scholar]
  15. Packer M., Gottlieb S. S., Blum M. A. Immediate and long-term pathophysiologic mechanisms underlying the genesis of sudden cardiac death in patients with congestive heart failure. Am J Med. 1987 Mar 20;82(3A):4–10. doi: 10.1016/0002-9343(87)90126-4. [DOI] [PubMed] [Google Scholar]
  16. Packer M. Therapeutic options in the management of chronic heart failure. Is there a drug of first choice? Circulation. 1989 Jan;79(1):198–204. doi: 10.1161/01.cir.79.1.198. [DOI] [PubMed] [Google Scholar]
  17. Rademaker M., Shaw T. R., Williams B. C., Duncan F. M., Corrie J., Eglen A., Edwards C. R. Intravenous captopril treatment in patients with severe cardiac failure. Br Heart J. 1986 Feb;55(2):187–190. doi: 10.1136/hrt.55.2.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sharpe N., Smith H., Murphy J., Greaves S., Hart H., Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet. 1991 Apr 13;337(8746):872–876. doi: 10.1016/0140-6736(91)90202-z. [DOI] [PubMed] [Google Scholar]
  19. Urata H., Healy B., Stewart R. W., Bumpus F. M., Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990 Apr;66(4):883–890. doi: 10.1161/01.res.66.4.883. [DOI] [PubMed] [Google Scholar]
  20. Volpini M., Gargano M., Cuccia C., Dei Cas L., Gei P., Metra M., Moretti R., Riva S. Effetti emodinamici della somministrazione endovenosa di captopril in pazienti affetti da scompenso cardiaco congestizio cronico. Cardiologia. 1989 Jun;34(6):517–523. [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES